CD49f Can Act as a Biomarker for Local or Distant Recurrence in Breast Cancer.

CONCLUSION: Our results indicated that breast tumors with CD49f(+) cancer cells are associated with an increased risk for disease recurrence after initial surgery with poor clinical outcomes (decreased DFS). Therefore, as it requires testing for only one additional protein, adding CD49f testing to conventional surgical pathology is a strategy that has great potential for prognostic and treatment-guidance purposes. PMID: 28690650 [PubMed - in process]
Source: Journal of Breast Cancer - Category: Cancer & Oncology Tags: J Breast Cancer Source Type: research